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Sepsis represents a continuum of illness due to systemic inﬂammation caused by an infection that requires prompt recognition and treatment. While sepsis is a signif-
icant cause of death worldwide, its mortality is believed to be disproportionately high in low- and middle-income countries (LMICs). Since 1992, its deﬁnition has
become standardized, and beginning in 2002, an international collaboration has produced a set of consensus guidelines on the optimal management of septic patients.
Based on new evidence, signiﬁcant updates have been made since then. It is known that application of a bundled approach to patient care with the use of speciﬁc resus-
citation endpoints to guide therapy leads to signiﬁcant reductions in mortality from sepsis. However, it is also recognized that the implementation of such interventions
in LMICs is extremely challenging. Consequently, a body of literature on practical guidelines for sepsis in developing countries has emerged. This article provides a
review of the evidence for the best practice of sepsis management, with recommendations for resource-limited settings.La septice´mie repre´sente un e´ventail de maladies dues a` une inﬂammation syste´mique provoque´e par une infection qui ne´cessite une identiﬁcation et un traitement
rapide. Si la septice´mie est une cause de de´ce`s importante dans le monde, la mortalite´ associe´e est conside´re´e comme disproportionnellement e´leve´e dans les pays a`
faible et moyen revenus. Depuis 1992, sa de´ﬁnition s’est standardise´e, et a` partir de 2002, une collaboration internationale a produit un ensemble de lignes directrices
consensuelles sur la prise en charge optimale des patients souffrant de septice´mie. Sur la base de nouvelles donne´es factuelles, des mises a` jour d’envergure y ont depuis
e´te´ apporte´es. On sait que l’application d’une approche globale a` la prise en charge des patients, combine´e au recours a` des crite`res de re´animation visant a` guider la
the´rapie, permet d’obtenir une re´duction signiﬁcative de la mortalite´ lie´e a` la septice´mie. Il est cependant e´galement reconnu que la mise en œuvre de telles interventions
dans les pays a` faible et moyen revenu est extreˆmement difﬁcile. Par conse´quent, un certain nombre de publications sur les directives pratiques relatives a` la prise en
charge de la septice´mie dans les pays en voie de de´veloppement sont apparues. Cet article propose un examen des e´le´ments probants sur une meilleure pratique de la
gestion de la septice´mie, ainsi que des recommandations pour les milieux a` ressources limite´es.African relevance
 Sepsis has an especially high mortality in Africa.
 Rapid recognition of sepsis and a protocoled approach to
management save lives.
 Tailored recommendations for resource-limited settings
offer a practical approach to sepsis care.Introduction
In 1992, ‘‘sepsis’’ was formally deﬁned as the presence of both
suspected infection and two of the four criteria of the systemic
inﬂammatory response syndrome (SIRS) (Tables 1 and 2).1,2Since then, additional terminology has emerged. Sepsis compli-
cated by organ dysfunction is referred to as ‘‘severe sepsis,’’
while sepsis complicated by hypotension refractory to ade-
quate volume resuscitation in the absence of an alternate cause
has been termed ‘‘septic shock’’.1 The clinical signiﬁcance of
the sepsis spectrum of illness cannot be understated. In the
US alone, the incidence of severe sepsis is over 700,000 annu-
ally with an estimated 30% mortality.3 This is estimated to
represent over 450,000 emergency centre (EC) visits per year.
4 While some research has been devoted to the study of sepsis
in developing countries, its epidemiology in these countries
remains poorly described.5,6 Despite this, the morbidity and
mortality of sepsis in low- and middle-income countries
(LMICs) are believed to be disproportionately high, given
environmental degradation, widespread malnutrition, and
higher rates of bacterial, parasitic, and HIV infection.6,7 In
an effort to reduce the risk of death from sepsis, the Surviving
Sepsis Campaign (SSC) was initiated in 2002 from the collab-
oration of the European Society of Intensive Care Medicine
(ESICM), the International Sepsis Forum (ISF), and the
Society of Critical Care Medicine (SSCM). In 2004, the SSC
Table 1 SIRS criteria.1
Presence of two or more of the following.
1. Temperature  >38 C (100.4 F) or
 <36 C (96.8 F)
2. Heart rate  >90/min
3. Respiratory rate  >20/min or
 PaCO2 < 32 mmHg
4. White blood cell count  >12,000/lL or
 <4000/lL
Table 2 Diagnostic criteria for sepsis.1 WBC, white blood
cell; SBP, systolic blood pressure; MAP, mean arterial pressure.
Table adapted from Levy et al. (2003).1
Infection (documented or suspected) and some of the following.
Classiﬁcation Variables
General Fever (>38.3 C)
Hypothermia (core temperature < 36 C)
Heart rate > 90/min or more than two SD
above the normal value for age
Tachypnea
Altered mental status
Signiﬁcant oedema or positive ﬂuid balance
Hyperglycaemia
Inﬂammatory Leukocytosis
Leukopenia
Normal WBC count with greater than 10%
bands
Plasma C-reactive protein > 2 SD above the
normal value
Plasma procalcitonin > 2 SD above the
normal value
Hemodynamic Hypotension (SBP < 90 mmHg,
MAP< 70 mmHg, or an SBP
decrease > 40 mmHg in adults or < 2 SD
below normal for age)
Organ dysfunction Creatinine increase
Coagulopathy
Hypoxaemia
Ileus
Oliguria
Thrombocytopenia
Hyperbilirubinemia
Tissue perfusion Hyperlactatemia
Decreased capillary reﬁll or mottling
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management of severe sepsis and septic shock,’’ one of the
most recognized consensus statements regarding the treatment
of sepsis (most recently updated in 2012).8 In many countries,
it is held to be the standard of care.7 As 50% of hospital
admissions occur through the ED, there is a signiﬁcant oppor-
tunity to improve outcomes.9 This review will discuss the
epidemiology, pathophysiology, and diagnostic and therapeu-
tic approach to patients with sepsis, severe sepsis, and septic
shock in the ED and other acute care settings. It is important
to note that as international guidelines focus on the evaluation
and management of patients with severe sepsis and septic
shock (SS/SS) as opposed to sepsis without evidence of SS/SS, this article will primarily discuss SS/SS. A particular focus
will be on providing care in resource-limited settings with
tailored recommendations. Of note, this review pertains
speciﬁcally to adults and not to children. See Tables 1 and 2
for deﬁnitions.
Epidemiology
Despite the documented impact of sepsis in developed coun-
tries, literature on its incidence, prevalence, and mortality in
developing countries is sparse.10 What is recognized, however,
is that the global burden of sepsis lies in LMICs. As a surro-
gate marker for sepsis, over 90% of worldwide deaths due to
pneumonia, meningitis, and other infections occur in less
developed nations.6,11 Globally, an estimated 70% of the 9
million annual neonatal and infant deaths are attributable to
sepsis, and more than half of these occur in Asia and Sub-
Saharan Africa.11,12
Pathophysiology
During infection, offending microbes interact with the host
immune system producing a downstream inﬂammatory cas-
cade involving cytokines and other mediators, which in turn
triggers a systemic response. The resultant effects include
vasodilation, increased vascular permeability, myocardial
depression, and impairment of the coagulation cascade,
resulting in global imbalance of systemic oxygen supply
and demand, and a procoagulant state. During the late stage
of sepsis, immunosuppression predominates, leading to
multiorgan dysfunction and further clinical deterioration.13
Clinical assessment
During history taking, the focus should be on detecting risk
factors for infection (such as immunosuppression), the pres-
ence of infection, and if suspected, the most likely sources.
Caution should be advised in geriatric patients, as they may
not be able to communicate traditional symptoms (e.g., dys-
uria in occult urinary tract infections). The physical examina-
tion should be used to identify possible foci of source control.
A critical action at this point is the measurement, documenta-
tion, and evaluation of vital signs, including temperature,
blood pressure (BP), heart rate (HR), respiratory rate (RR)
and oxygen saturation (if below 90% then supplemental
oxygen should be immediately applied). Repeated recording
of these parameters will be used to gauge clinical improvement
or deterioration and trigger speciﬁc interventions (see below).
Consistently analysing the vital signs for the presence of SIRS
criteria in any possible patient with sepsis will aid in the early
recognition of critical illness.
Importantly, vital sign derangements may be absent early
on and in elderly patients.14,15 Speciﬁc physical exam ﬁndings
that are predictive of sources of infection include indwelling
devices (e.g., intravascular or urinary catheters), rales,
abdominal tenderness, and evidence of CNS infection.16,17 A
cardiovascular and volume status assessment, including
auscultation, mucous membranes, skin colour and turgor,
peripheral pulses, capillary reﬁll and oedema should be
undertaken at this stage as well.
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imperative to keep a written log and to have early recognition
of SIRS. As more advanced and invasive equipment used to
gauge response to therapy (see below) may be absent in
LMICs, changes in BP, HR, RR and oxygen saturation to
interventions should be used as indicators of clinical status.
Diagnostic studies
Initial laboratory and radiographic testing is aimed at locating
a source of infection and identifying evidence of organ dys-
function. At the discretion of the examiner, common labora-
tory studies include a complete blood count (white blood cell
count including a differential of subtypes and measure of
bands, haemoglobin and haematocrit, platelets), chemistries
(electrolytes, bicarbonate, creatinine, glucose), prothrombin
time (PT)/international normalized ratio (INR), liver transam-
inases, bilirubin, and either arterial or venous blood gas anal-
ysis with the inclusion of a serum lactate level. Urinalyses are
of high-yield, particularly in patients older than 65.18 Chest
radiography is often sought to identify sources of pulmonary
infection and causes of respiratory distress. Importantly, all
patients with possible sepsis should have blood cultures drawn
as they may narrow antibiotic choices and uncover reasons for
treatment failure.8 As the volume of blood is more important
for culture yield than the number of blood cultures, ideally,
20 mL of blood should be collected.19 In general, cultures
should be obtained from every possible source of infection
(e.g., blood, urine, sputum, wounds, catheters, cerebrospinal
ﬂuid) deemed likely in the clinical scenario.
If only select laboratory tests are available, preference
should be given to those that may indicate a source of infec-
tion, consequently identifying a target for therapy. Blood cul-
tures should be obtained whenever possible.
Treatment and management
General approach
Prompt recognition of the septic patient is critical, and early
localization along the sepsis spectrum of illness (sepsis, severe
sepsis, septic shock) helps to deﬁne the early goals of manage-
ment. A key distinction should be made between sepsis and
severe sepsis/septic shock (SS/SS), the latter of which are the
focus of the Surviving Sepsis Campaign guidelines. It is recom-
mended that patients with SS/SS undergo a protocol-driven
approach to treatment using quantitative resuscitation.8 This
is the concept of using explicit, predeﬁned physiological or lab-
oratory resuscitation endpoints to guide management.20 Its
international recognition was sparked by a landmark study
by Rivers in 2001, which utilized a goal-directed approach to
therapy of SS/SS patients (early goal-directed therapy, EGDT)
and demonstrated a 16% absolute reduction in in-hospital
mortality (number needed to treat = 6.25).21 A 2008 meta-
analysis provided further support for the use of early and
quantitative resuscitation as it showed a survival beneﬁt in het-
erogeneous populations with sepsis.22 Of note, however, the
ProCESS trial, a recent multicenter randomized trial of over
1300 patients demonstrated no mortality beneﬁt with the use
of protocol-based resuscitation (such as EGDT) over ‘‘usual’’(provider-driven) care.23 It is critical to note, however, that
patients in the ‘‘usual’’ care group were aggressively resusci-
tated (in the ﬁrst 6 h of EC arrival: 4.4 L of intravenous ﬂuids,
58% had central venous catheters, 44% were placed on vaso-
pressors, 22% underwent mechanical ventilation), and in the
absence of this high level of ‘‘usual’’ care, protocol-based
resuscitation may still be advocated.
Some of the markers of resuscitation and their usage (e.g.,
central venous pressure, CVP; mean arterial pressure, MAP;
central venous oxygen saturation, ScvO2, serial lactate) will
be discussed below.
Patients with hypotension despite ﬂuid resuscitation and
those with evidence of end organ dysfunction (SS/SS) have
high mortalities and aggressive resuscitation or adherence to
protocoled, goal-oriented therapy may improve mortality.
Using as many of the available following techniques can alter
the course of illness. Upon recognition of SS/SS, a team of care
providers should be alerted and enlisted.
Initial resuscitation
The initial evaluation of patients with sepsis includes the rapid
establishment of multiple points of intravenous (IV) access
with anticipation for the need for ﬂuid resuscitation, antimi-
crobials, and possibly vasoactive medications (vasopressors).
As patients are often hypovolaemic, frequently suffering large
ﬂuid deﬁcits, immediate administration of 30 mL/kg (typically
2 L) of crystalloid is recommended.8,24 The goal is to restore
tissue perfusion, and volume resuscitation leads to increases
in cardiac output and systemic oxygen delivery.24 Patients with
hypotension (MAP< 65 mmHg) after a ﬂuid bolus, hyperlac-
tatemia (>4 mmol/L), signs of hypoperfusion or organ failure
are deemed to be in SS/SS. In such instances, transition to a
goal-directed approach to therapy is recommended by consen-
sus guidelines with measurable endpoints at the 3- and 6-h
marks.8 It is important to note that patients meeting criteria
for sepsis but not SS/SS may beneﬁt from a similar approach
to therapy. However, consensus guidelines advocating bundled
care pertain speciﬁcally to SS/SS patients.8
In resource limited settings, administer at least 30 mL/kg
(typically 2 L) of crystalloid upon the recognition of sepsis,
as many patients are hypovolaemic.
Measures of intravascular volume
The ﬁrst protocoled step in the care of patients with SS/SS is
ﬂuid resuscitation with the goal of restoring intravascular vol-
ume (and presumptively, preload).8 There are several methods
to estimate volume status that are gaining support, such as
ultrasound-guided assessment of the respirophasic variation
of the inferior vena cava (IVC), and pulse-pressure variation
(PPV).25 However, the efﬁcacy of these monitoring techniques
in improving clinical outcomes is believed to require further
study.8 As such, consensus guidelines continue to recommend
CVP measurement as a surrogate for preload despite a well-
known systemic review demonstrating a very poor relationship
between CVP and ﬂuid responsiveness.8,26 Consequently, the
ﬁrst resuscitation endpoint in SS/SS according to the Surviving
Sepsis Campaign guidelines is a target CVP of 8–12 cm
H2O. Values signiﬁcantly below this may be suggestive of
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citation. It is worth highlighting here that utilizing CVP requires
the placement of a central venous catheter above the diaphragm.
In the resource-limited setting, be aggressive in empirically
ﬂuid loading patients as they may require more than 4–6 L of
crystalloid in the ﬁrst 6 h of care.21 This intervention alone has
been shown to reduce mortality.27 As shown in the ProCESS
trial, aggressive ﬂuid resuscitation (an average of 4.4 L in the
ﬁrst 6 h in this study) should be the norm.23 In the absence
of advanced modalities to estimate ﬂuid responsiveness, check
jugular venous distension and listen for crackles as evidence of
ﬂuid overload.28
Ongoing ﬂuid administration
While highly variable by case, patients in the ProCESS trial
usual care arm received an average of 4.3 ± 3.9 L of intrave-
nous ﬂuid from hours 6 to 72 (after initial resuscitation).23
In resource-limited settings, use markers of hypoperfusion
such as hypotension, lactate clearance, and urine output (see
below) to guide the rate of ﬂuid administration following the
initial resuscitation period. While variable, this may be in
excess of 8 L over the following 72 h.
Fluid selection
The results of numerous trials support the preferential use of
crystalloid, the avoidance of hydroxyethyl starches (HES),
and the select use of albumin only after large quantities of crys-
talloid administration. Crystalloid has repeatedly shown to be
cheaper, and has either no mortality difference or a lower mor-
tality in comparison HES, along with a decreased need for
renal replacement therapy (RRT) and is strongly recom-
mended.8,29,30 Additionally, it is important to note that while
there are emerging data on the potential beneﬁts of using bal-
anced crystalloid solutions (e.g., Ringer’s lactate) as opposed
to chloride-rich ﬂuids (e.g., normal saline), the primary consid-
eration in LMICs should be on ensuring adequate crystalloid
volume resuscitation regardless of the type.31,32 It is important
to reiterate here that this review focuses on adult patients, as a
study of over 3000 children in shock with febrile illnesses who
were randomized to ﬂuid boluses vs. no boluses demonstrated
an increased mortality in the ﬂuid bolus group.33 The applica-
bility of this trial to adult patients has yet to be established.
In resource-limited settings, use crystalloids liberally. The
type of crystalloid infusion is not as important as the volume
given.
Vasopressors
The second resuscitation endpoint in SS/SS is the establish-
ment of a MAP of at least 65 mmHg. In SS/SS, there is an
imbalance between vasodilation and vasoconstriction. Accord-
ingly, vasoactive medications are often required in septic
patients with hypotension (MAP< 65 mmHg). Their purpose
is to restore adequate arterial pressures and blood ﬂow to vital
organs. Below MAPs of 60 mmHg, coronary, renal and CNS
autoregulation are lost and organ blood ﬂow has a linear rela-
tionship with pressure.34 However, tissue perfusion can be
maintained at MAPs as low as 65 mmHg.35 As such, whenusing vasopressors, targeting a MAPP 65 mmHg is an
accepted clinical end point for most patients.8 An important
caveat is that higher MAPs may be required in patients with
chronic hypertension and lower MAPs may be tolerated in
young patients.8 Ideally, ﬂuid resuscitation (CVPP 8 cm
H2O) should occur prior to the use of vasopressors, however,
patients in shock may require them to be started sooner.8
There are several options for choice of vasopressor agent.
In the Rivers study, dopamine and norepinephrine were
used.21 In a recent, multicenter trial comparing norepinephrine
and dopamine, both were deemed equally efﬁcacious at revers-
ing hypotension and there was no signiﬁcant difference in mor-
tality, though there were more arrhythmias in the dopamine
group.36 The authors concluded that norepinephrine is
superior in the setting of sepsis.36
In patients with refractory hypotension despite ﬂuid resus-
citation and norepinephrine administration, vasopressin may
be added at low doses of 0.03 units per minute and has been
shown to have beneﬁcial hemodynamic and renal function
effects.37 Epinephrine and phenylephrine are alternative addi-
tions to norepinephrine.8
The newest consensus guidelines recommend norepineph-
rine as the ﬁrst-line vasopressor, while epinephrine and vaso-
pressin are possible additions. Dopamine is recommended
against being used except in highly select circumstances, such
as relative bradycardia.8
In resource-limited settings, vasopressors should be initi-
ated once patients are believed to be adequately ﬂuid resusci-
tated. If available, norepinephrine is preferred, followed by
epinephrine and/or vasopressin. Dopamine and phenylephrine
may be used if no other agent is available.
Blood products and inotropes
The third resuscitation endpoint for the treatment of SS/SS is a
SCVO2 of at least 70%, as a measure of the balance between
tissue oxygen delivery and consumption. There are several
causes of low central venous oxygen saturations (SCV-
O2 < 70%) in septic patients who have achieved adequate
ﬂuid resuscitation and adequate blood pressure. This may be
due to metabolically active tissue, arterial hypoxaemia, low
oxygen carrying capacity, or decreased cardiac output. The
degree of oxygen delivery can be improved by the transfusion
of packed red blood cells.21
Red blood cells should be transfused to a target haemoglo-
bin concentration of 7–9 g/dL.8 This differs from the Rivers
study, which used a threshold haematocrit of 30%.21 However,
while the optimal haemoglobin concentration in sepsis is not
speciﬁcally known, results from the Transfusion Requirements
in Critical Care trial did not demonstrate increased mortality
when using a haemoglobin count of 7–9 g/dL compared to
10–12 g/dL.38 Routine administration of fresh frozen plasma
to correct a coagulopathy should be avoided unless there is
active bleeding or a planned invasive procedure. Platelets
should be transfused below 5000/mm3 even in the absence of
bleeding, and may be considered between 5000 and 30,000/
mm3 if there is a signiﬁcant risk of bleeding. If the platelet count
is 50,000/mm3 or above then transfusion should only take place
in the setting of planned surgery or invasive procedures.8
If ScvO2 is less than 70% despite an appropriate haemoglo-
bin level (above), inotropic agents may be administered to
Sepsis, severe sepsis, and septic shock 131augment cardiac output. Dobutamine (2.5 mcg/kg/min to
maximum 20 mcg/kg/min) is the agent of choice.21 Exceeding
this dose has not been shown to be effective.
In resource-limited settings, blood product transfusions
should be used sparingly, as indicated above. Inotropic ther-
apy can be initiated to augment cardiac output if evidence of
shock persists despite liberal ﬂuid administration, vasopressor
initiation, and blood product transfusion (if indicated).
As SCVO2 measurement requires a central venous catheter
(CVC), other measures of shock such as lactate and urine
output (see below) can be used as surrogate indicators.
Lactate
Lactate is an important marker of severe sepsis and elevated
levels (P4 mmol/L) are associated with a high mortality rate.39
A recent multicenter randomized trial by Jones compared lac-
tate clearance (P10%) with SCVO2 (P70%) as a quantitative
resuscitation endpoint and found it to be noninferior.40 This
suggests that measuring peripheral lactate levels instead of
SCVO2 (which requires a CVC) may spark a noninvasive path-
way of quantitative resuscitation. However, this possibility has
yet to be included in consensus guidelines, which currently
state a goal of lactate normalization.8 Importantly, SCVO2
and lactate need not be used to the exclusion of one another,
and when available, can be used concurrently.
In the absence of CVCs, checking serial lactate levels for
clearance can be used to guide therapy (above)
Urine output
Regardless of whether SCVO2 or lactate levels are used to guide
therapy, resuscitation within the ﬁrst 6 h includes the mainte-
nance of urine outputP 0.5 mL/kg/h. This is a supplemental
endpoint to other markers of tissue perfusion, and low levels
suggest the need for more aggressive resuscitation.8
In resource-limited settings, urine output should be
measured for all patients. An indwelling urinary catheter can
be used, or a urine collection container. The time and amount
of each voiding episode should be recorded, similar to the vital
signs.
Antimicrobials
In the setting of SS/SS, it has been demonstrated that delayed
antibiotic administration is clearly associated with increased
mortality. Even prior to the onset of persistent or recurrent
hypotension, there is an 8% increase in mortality for each hour
of delay in antimicrobial administration.41 In another cohort
of patients undergoing EGDT, those who received appropriate
antibiotics less than one hour after triage had a 14% lower
mortality than those who did not.42 While timing is essential,
antibiotic choice is similarly important. Targeting the offend-
ing pathogens has outcome implications as well. In a prospec-
tive study, Gram-negative bacteraemia patients who
empirically received appropriate (pathogen susceptible)
antibiotics had a signiﬁcantly lower mortality than those
who empirically received inappropriate (pathogen not suscep-
tible) antibiotics (18% vs. 34%).43 Not surprisingly, patients
who receive inadequate therapy have a 10% increase in
hospital mortality.41 As such, it is recommended thatbroad-spectrum antibiotics be given as soon as possible in sep-
sis, but always within the ﬁrst hour after recognition of SS/SS.8
While the feasibility of this requires further study, and is not yet
the international standard of care, the importance of adminis-
tering correct antibiotics as soon as possible cannot be
overstated.39
The choice of empirical antibacterial therapy varies signiﬁ-
cantly based on patient characteristics. Important consider-
ations include (but are not limited to): the most likely
source(s) of infection, recent antibiotics (last 3 months), recent
healthcare exposure (e.g., hospitalization), underlying chronic
disease, local pathogens and drug resistance.8 Patients with
recent antibiotic exposure have an elevated incidence of
high-risk infections such as methicillin-resistant Staphylococ-
cus aureus and Pseudomonas aeruginosa, whereas those with
recent healthcare exposure have increased likelihood of being
colonized with ESBL-producing bacteria.44 Importantly, the
most common pathogens in SS/SS among hospitalized patients
in the descending order are Gram-positive bacteria, Gram-neg-
ative bacteria, and mixed bacterial microorganisms.8 In all
cases, antibacterial therapy should be guided by the most likely
sources of infection along with local antibiograms.
In addition to bacteria, fungi have emerged worldwide as
growing causes of infection, particularly in the hospital setting,
and Candida is the fourth most common agent identiﬁed in
blood cultures of septic patients. Despite this, it is estimated
that fungi are responsible for only 5% of all cases of SS/SS,
and therefore, the routine administration of antifungals is
not recommended. Rather, they should be reserved for select
patients with known Candida colonization at multiple sites,
impaired physiologic barriers (recurrent gastrointestinal perfo-
rations or anastomotic leakages, acute necrotizing pancreatitis,
chemotherapy-induced mucositis, vascular access devices)
immunocompromised states (neutropenic cancer patients or
transplant recipients), or failure to improve while receiving
antibiotics.45 First-line agents are azoles or echinocandins.46
In resource-limited settings, rapid administration of appro-
priate antibiotics is a cornerstone to sepsis care and has a time-
sensitive effect on mortality. Antibiotics should be started as
soon as possible (ideally within the ﬁrst hour of the recognition
of sepsis). Important patient characteristics include recent use
of antibiotics and healthcare exposure. Local or regional anti-
biotic guidelines are preferred and should be used to choose
the most appropriate agent(s). Consider the addition of an
antiviral agent in select cases.28
Malaria
In Sub-Saharan Africa, malaria co-infection with sepsis is
common in children. In a study of over 3000 children in
Uganda, Kenya and Tanzania with febrile illnesses, 57% were
found to have malarial infection.33 In another study of chil-
dren with malaria, 6% had concomitant invasive bacterial
infection along with associated increased mortality.47 In
adults, however, the co-infection rate is less clear, with a recent
study of septic adults in Uganda, a malaria-endemic area,
demonstrating a malarial prevalence of only 4%.48
As there are many forms of rapid diagnostic tests (RDTs)
for malarial antigens (e.g., histidine-rich protein 2, Plasmodium
lactate dehydrogenase) now in use in endemic areas, parasito-
logical conﬁrmation has risen from 20% to 47% from 2005
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tive predictive values to support withholding treatment in the
presence of severe illness, and presumptive antimalarial treat-
ment for febrile illnesses has long been recommended.50–54
In resource-limited settings, while there is insufﬁcient
evidence to recommend empiric antimalarial treatment in all
adult patients with SS/SS, if there is clinical concern for
concomitant malarial infection, empiric treatment should be
started and guided by local resistance patterns.
Source control
Removing the source of infection is important as well and is
termed ‘‘source control.’’ It includes interventions such as ﬂuid
drainage, debridement of soft tissues, device removal, and
other deﬁnitive measures to restore function. The physical
removal of an ongoing locus of infection should be identiﬁed
or excluded as soon as possible as it can rapidly alter the
course of sepsis.8,55 Interventions should start with the least
invasive method (e.g., percutaneous as opposed to surgical)
when possible. When vascular catheters are left indwelling,
blood cultures should be sent from them. Indwelling urinary
catheters should be replaced and a urine culture should be sent
from the new catheter.17
In resource-limited settings, remove the source of infection
whenever possible, particularly if it can be drained or
debrided.11
Corticosteroids
SS/SS may be associated with a relative adrenal insufﬁciency.56
As such, several studies have attempted to determine whether
the routine administration of corticosteroids may aid the reso-
lution of shock and improve overall mortality. As anti-inﬂam-
matory agents, it is theorized that corticosteroids may reduce
the tissue damage caused by cytokines and neutrophils.13 Early
on, corticosteroids were not shown to be beneﬁcial in SS/SS
and in fact, potentially worsened outcomes.57 However, a later
study by Annane et al demonstrated that patients with vaso-
pressor-unresponsive septic shock developed shock reversal
and mortality reduction when treated with low-dose hydrocor-
tisone and ﬂudrocortisone.58 A follow-up, large multicenter
trial (CORTICUS), which included septic shock patients
who responded to vasopressors, did not show a survival beneﬁt
for patients receiving low-dose steroids.59 As such, consensus
guidelines recommend against the routine use of hydrocorti-
sone if IV ﬂuids and vasopressors can restore hemodynamic
stability. In the event of vasopressor-unresponsive shock,
hydrocortisone at a dose of 200 mg IV daily is suggested.8
In resource-limited settings, steroids, when available,
should be reserved for persistent septic shock following ade-
quate ﬂuid resuscitation and administration of vasopressors.
Glucose
While it was previously believed that tight glycaemic control
(blood glucose 80–110 mg/dL) was beneﬁcial, data from the
NICE-SUGAR trial have demonstrated increased mortality
with this approach compared to conventional glucose control
(blood glucose 6 180 mg/dL).60 It is now recommended thata protocoled approach to insulin dosing begins only after
two blood glucose measurements > 180 mg/dL.8
In resource-limited settings, check blood glucose levels on
all patients. In the presence of mild hyperglycaemia, without
close monitoring, be cautious about reducing glucose levels,
as precipitating hypoglycaemia may be more harmful.
Intubation and mechanical ventilation
In septic patients, the development of shock in the ﬁrst 24 h is
the best predictor of the need for mechanical ventilation, and
half of all patients with this severity of illnesses go on to
develop acute respiratory distress syndrome (ARDS).61
Endotracheal intubation and mechanical ventilation can help
by decreasing work of breathing and improving oxygen
delivery.8,21 When required, the decision should be made early
on. There are several options for induction agents in rapid
sequence intubation (RSI) and there is debate as to which is
the most favoured.
Etomidate is a commonly used induction agent in the Uni-
ted States. Its use in sepsis has become a focus of discussion,
particularly in recent years as the CORTICUS study showed
that patients receiving etomidate had a 17% increased rate
of adrenal suppression and increased risk of death at 28 days
(40–45% vs. 30–32%).59 However, since that time, several pro-
spective and retrospective studies have not shown a statistically
signiﬁcant increase in mortality with the use of etomidate.62–65
As such, there are no deﬁnitive data at this time preventing the
use of etomidate in SS/SS. There are, however, advantages to
other agents such as ketamine, which has drawn attention due
to its sympathomimetic effects on heart rate, blood pressure,
and cardiac output.66,67 Presently, the choice of induction
agent is clinician-dependent.
The inﬂammatory response to sepsis can cause lung injury
and the development of ARDS. In a landmark multicenter
randomized trial of lung-injured patients, those who under-
went mechanical ventilation with lung-protective ventilation
(low tidal volumes of 6 mL/kg of predicted body weight and
low plateau pressures 6 30 cm H2O) had a 9% absolute reduc-
tion in mortality.68 As such, this is the preferred ventilation
strategy. Following intubation, fractions of inspired oxygen
(FiO2) should be reduced as soon as possible to prevent oxygen
toxicity. Maintaining low levels of positive end-expiratory
pressure (PEEP) can prevent extensive alveolar collapse at
end-expiration.8,41,61 Additionally, the head of the bed should
be elevated 30–45 as it has prospectively been shown to reduce
the rate of ventilator-associated pneumonia.69
In resource-limited settings, use pulse oximetry routinely
and keep oxygen levels above 90% by administering supple-
mental oxygen.
Summary
Consensus guidelines exist with speciﬁc recommendations for a
bundled approach to the treatment of septic patients, and in
particular, those with SS/SS. The concept of quantitative
resuscitation has gained support in recent years and has helped
standardize the approach to the care of sepsis. What is
included above is the inclusion of ideal practices. Key points
include:
Table 3 Sepsis interventions in resource-limited settings.11 Table adapted from Dunser et al. (2012).11
Resource-limited interventions
Category Intervention
Circulation  Target adequate tissue perfusion as the primary endpoint of resuscitation. Additionally, aim for a blood
pressure > 90 mmHg
 When there is evidence of hypoperfusion, infuse crystalloid ﬂuids aggressively and continue liberal infusions for 24–
48 h. Patients may require more than 4 L during the ﬁrst 24 h
 Preferentially use norepinephrine in patients with hypoperfusion despite liberal ﬂuid resuscitation. Monitor blood
pressure and heart rate frequently
 Reserve steroids for patients requiring escalating doses of vasopressors
Oxygenation  Apply oxygen with goal oxygen saturation > 90%. Administer empiric oxygen in patients with SS/SS in the absence of
a pulse oximeter
Antimicrobial therapy  Administer antimicrobials within 1 h of recognizing sepsis
 Choose antimicrobials with a high likelihood to be active against the suspected pathogens
Diagnosis  Gather a detailed patient history and perform a thorough examination, seeking to identify the source of infection
 Use imaging techniques when available
 Obtain cultures from every likely source of infection and test for antimicrobial sensitivities
Source control  Drain or debride the source of infection when possible
 Remove any foreign body or device that may be the source of infection
Sepsis, severe sepsis, and septic shock 133 Rapid screening using SIRS criteria and vigilant recogni-
tion of the sepsis spectrum of illness.
 Continually repeated vital signs.
 Supplemental oxygen for oxygen saturation levels < 90%.
 Immediate intravenous access at multiple sites.
 Fluid resuscitation usingP 30 mL/kg of crystalloid fol-
lowed by intravascular volume assessment.
 Maintenance of MAPP 65 mmHg and the use of vasopres-
sors (norepinephrine ﬁrst line) if necessary.
 The use of blood products (haemoglobin 7–9 g/dL) and/or
dobutamine to keep SCVO2P 70% (when available).
 Measurement and normalization of lactate levels.
 Cultures obtained from every suspected source of infection.
 Administration of broad-spectrum antibiotics as quickly as
possible (ideally within the ﬁrst hour).
 Early source control.
 Avoidance of corticosteroids except in vasopressor-unre-
sponsive shock.
 Conventional glucose control 6 180 mg/dL.
 Ventilation with low tidal volumes (6 mL/kg).
 Continued reassessment of clinical status and revaluation of
treatment modalities.
African relevance
While the Surviving Sepsis Campaign guidelines have gained
international recognition and led to improved outcomes for
SS/SS patients in developed countries, many of the recommen-
dations cannot be implemented within LMICs due to a lack of
resources.7,70,71 For example, in many circumstances, one of
the most fundamental of needs, stafﬁng for appropriate patient
monitoring, is inadequate, and there is poor access to higher
levels of care such as intensive care units.7,72 Furthermore,
there is debate about the transferability of some studies per-
formed in high-income countries.73 Nonetheless, there exists
evidence that a bundled approach to sepsis care in the develop-
ing world, focused on early ﬂuid and antibiotic administration
improves mortality in Africa.74
There are no accepted guidelines for SS/SS management in
LMICs. However, several evidence-based recommendationshave been generated in their absence. They highlight the high
rate of HIV and other potentially contributing infectious dis-
eases (such as malaria and typhoid fever), regional variation
in bacteriology, and emphasize the importance of rapid recog-
nition of sepsis and the need for additional training and
research.6,11,75 Table 3 is a summary of a systematic review of
best-practice interventions tailored to resource-limited settings.
Future directions
Much is needed in the way of research pertaining to the care of
septic patients in LMICs. Particular areas of focus include the
epidemiology of sepsis, availability of resources in non-tertiary
care settings, efﬁcacy of bundled care and the relative efﬁcacy
of speciﬁc targeted interventions, health care worker knowl-
edge and training programs, and cost-beneﬁt analysis of each
of these components.
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